Figure 1

Alkaline secretion. Effects of intravenous administration of the AT2-receptor agonist CGP42112A (0.1 μg kg^-1 min^-1) alone (n = 7), or combined with L-NAME (0.3 mM) in the luminal perfusate (n = 6) or intravenous injection of the BK2-receptor blocker HOE140 (100 ng/kg) (n = 5). Displayed also are untreated time controls receiving only vehicle (NaCl 150 mM) (n = 6). Data shown are means(SEM).